References

  1. National Cancer Institute. Concurrent chemoradiation for cervical cancer. Washington DC. February 22, 1999. Google Scholar

  2. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6. PubMed | Google Scholar

  3. Barillot I, Horiot JC, Pigneux J, Schraub S, Pourquier H, Daly N, Bolla M, Rozan R. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):969-78. PubMed | Google Scholar

  4. Coia L, Won M, Lanciano R, Marcial VA, Martz K, Hanks G. The Patterns of Care Outcome Study for cancer of the uterine cervix. Results of the Second National Practice Survey. Cancer 1990 Dec 15;66(12):2451-6. PubMed | Google Scholar

  5. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992; 23(2):457-67. PubMed | Google Scholar

  6. Fyles A, Keane TJ, Barton M, et al. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol. 1992 Dec;25(4):273-9. PubMed | Google Scholar

  7. Borowsky ME, Elliott KS, Pezzullo JC, Santoso P, Choi W, Choi K, Abulafia O. A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer. Bull Cancer. 2005; 92:E19-E24. PubMed | Google Scholar

  8. Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol. 1999 May;73(2):184-90. PubMed | Google Scholar

  9. Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004 May; 93(2):458-64. PubMed | Google Scholar

  10. Grigiene R1, Valuckas KP, Aleknavicius E, Kurtinaitis J, Letautiene SR. The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone. BMC Cancer. 2007 Dec 22; 7:234. PubMed | Google Scholar

  11. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999 Oct 15; 86(8):1528-36. PubMed | Google Scholar

  12. Winter WE III, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G, Carlson JW. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2004 Aug; 94(2):495-501. PubMed | Google Scholar

  13. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009 May;105(2):107-8. PubMed | Google Scholar

  14. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Sep;38(3):352-7. PubMed | Google Scholar

  15. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL. Wright JD Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012 May; 125(2):287-91. PubMed | Google Scholar

  16. Gustavo A Viani, Gustavo B Manta, Eduardo J Stefano, Ligia I de Fendi. Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy'a meta-analysis of clinical trials. J Exp Clin Cancer Res. 2009 Apr 5; 28:47. PubMed | Google Scholar

  17. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988; 27(2):131-46. PubMed | Google Scholar

  18. Girinsky T, Rey A, Roche B et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1051-6. PubMed | Google Scholar

  19. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix: Impact of prologation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88. PubMed | Google Scholar

  20. Lanciano RM, Pajak TF, Martz K et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a Patterns of Care Study. Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7. PubMed | Google Scholar

  21. Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1301-7. PubMed | Google Scholar

  22. Chen SW, Liang JA, Yang SN, Ko HL, Lin FJ. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol. 2003 Apr;67(1):69-76. PubMed | Google Scholar